This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 542 studies, archived under the term: "middle aged"

Click here to filter this large number of results.

New insights into clinical trial for Colostrinin in Alzheimer’s disease

Background: The pathomechanism of Alzheimer’s disease (AD) is multifactorial although the most popular hypotheses are centered on the effects of the misfolded, aggregated protein, amyloid beta (Abeta) and on Tau hyperphosphorylation.; Objectives: Double blinded clinical trials were planned to demonstrate the effect of Colostrinin (CLN) on instrumental daily activities of AD patients. The potential molecular […]

Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins

Purpose: Huntington disease (HD) mutation increases gain-of-toxic functions contributing to glutamate-mediated excitotoxicity. Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration.; Methods: We investigated metabolic and volumetric differences in distinct brain areas between 11 riluzole-treated […]

Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia

Background/aims: To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer’s disease, vascular dementia or both.; Methods: This is an 8-week, multicenter, randomized, double-blind, placebo-controlled trial carried out independently of the pharmaceutical industry. Changes in the agitation and aggression subscore of the Neuropsychiatric Inventory (NPI) were the […]

Predictors of long-term treatment effect of rivastigmine in Alzheimer’s disease: a role for beta-amyloid plasma levels?

Background and Purpose: Cholinesterase inhibitors (ChEI) are currently the mainstream symptomatic treatment of patients with Alzheimer’s disease (AD). To this end, the response to the treatment with ChEI is clinically difficult to predict. Several demographic, clinical and biological variables have been proposed as pre-treatment predictors of long-term therapy efficacy. The aim of the study was […]

Long-term effects of rivastigmine capsules in patients with traumatic brain injury

Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]

Use of multisensory environments in the home for people with dementia

The purpose of this pilot study was to explore the feasibility and effectiveness of using multisensory environments (MSE) in the home of people with dementia. A qualitative research design was used, which included semi-structured interviews and self-rated caregiver observation checklists. Field notes and audio recorded interviews were transcribed for data analysis. Data were reduced and […]

Addenbrooke’s Cognitive Examination validation in Parkinson’s disease

Background: There is a clear need for brief, sensitive and specific cognitive screening instruments in Parkinson’s disease (PD).; Objectives: To study Addenbrooke’s Cognitive Examination (ACE) validity for cognitive assessment of PD patient’s using the Mattis Dementia Rating Scale (MDRS) as reference method. A specific scale for cognitive evaluation in PD, in this instance the Scales […]

A prospective study of ventriculo-peritoneal shunting for idiopathic normal pressure hydrocephalus

Idiopathic normal pressure hydrocephalus (INPH) is a potentially treatable form of dementia but its diagnosis is difficult and the effectiveness of shunting remains controversial. This study investigates the clinical outcomes of ventriculo-peritoneal shunting in a controlled trial of 33 consecutive patients with INPH. Mean age was 77.2 years (range 58-92 years) and the duration of […]

A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer’s, vascular, or mixed dementia

Objectives: To evaluate the tolerability of intramuscular (IM) aripiprazole in patients with agitation associated with dementia.; Design: A 24-hour, double-blind, placebo-controlled, randomized study.; Setting: Sixteen healthcare facilities in the United States.; Participants: A total of 129 patients with acute agitation associated with Alzheimer’s, vascular or mixed dementia in healthcare facilities.; Intervention: Patients were randomized to […]

Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil

Objectives: Change in cognitive function in response to a pharmacologic challenge can be observed with greater sensitivity by employing cognitive tests with optimal psychometric properties and a statistical approach that more accurately accounts for individual variability in performance. To demonstrate this approach we examined the cognitive effects of a single acute dose administration of an […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below: